Iron therapy in chronic kidney disease: Recent changes, benefits and risks

Area of Science:

• Nephrology
• Hematology
• Clinical Pharmacology

Background:

• Anemia is a frequent complication in chronic kidney disease (CKD) patients, often linked to insufficient erythropoietin production.
• Iron deficiency (absolute or functional) can exacerbate anemia in hemodialysis (HD) patients.
• Erythropoiesis-stimulating agents (ESAs) and iron are standard treatments for CKD anemia.

Purpose of the Study:

• To review the risks of increased iron administration in CKD patients.
• To evaluate the potential for iron overload and toxicity.
• To assess the impact of current anemia treatment guidelines on iron levels and associated health outcomes.

Main Methods:

• Literature review focusing on studies related to anemia management in CKD.
• Analysis of current guidelines for treating anemia in CKD patients, particularly regarding iron supplementation.
• Examination of reported adverse events and outcomes associated with elevated iron levels.

Main Results:

• Current guidelines recommend iron trials when transferrin saturation <30% and ferritin <500 ng/mL to minimize ESA use.
• Recent observations indicate rising ferritin levels (>800 ng/mL) in CKD patients managed under these guidelines.
• Increased iron administration is associated with potential risks including iron overload, toxicity, and heightened susceptibility to infections.

Conclusions:

• The current approach to managing CKD anemia may inadvertently lead to excessive iron accumulation.
• Iron overload in CKD patients poses significant risks, including increased infection rates and mortality.
• A re-evaluation of iron management strategies in CKD patients is warranted to balance anemia treatment with safety concerns.